Capital Fund Management (CFM)’s Alexion Pharmaceuticals ALXN Stock Holding History

Capital Fund Management (CFM)’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-49,084	Closed	-$5.51M	–	1442
2020 Q2	$5.51M	Buy	+49,084	New	+$5.21M	0.09%	284
2020 Q1	–	Sell	-42,465	Closed	-$4.17M	–	2170
2019 Q4	$4.59M	Buy	+42,465	New	+$4.54M	0.04%	564
2017 Q3	–	Sell	-478,692	Closed	-$58.2M	–	1813
2017 Q2	$58.2M	Buy	478,692 +316,764	+196%	+$36.9M	0.47%	40
2017 Q1	$19.6M	Buy	+161,928	New	+$20.9M	0.16%	159
2016 Q3	–	Sell	-13,755	Closed	-$1.61M	–	1865
2016 Q2	$1.61M	Buy	+13,755	New	+$1.95M	0.02%	802
2015 Q4	–	Sell	-137,154	Closed	-$21.4M	–	1785
2015 Q3	$21.4M	Buy	+137,154	New	+$25M	0.24%	102
2015 Q2	–	Sell	-60,859	Closed	-$10.5M	–	1768
2015 Q1	$10.5M	Buy	60,859 +27,802	+84%	+$5.03M	0.14%	189
2014 Q4	$6.12M	Buy	33,057 +11,225	+51%	+$2.08M	0.07%	372
2014 Q3	$3.62M	Buy	+21,832	New	+$3.59M	0.04%	494
2013 Q3	–	Sell	-38,794	Closed	-$4.26M	–	1989
2013 Q2	$3.58M	Buy	+38,794	New	+$3.74M	0.05%	446

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Fund Management (CFM)'s ALXN Position: Q3 2020 in Review

Capital Fund Management (CFM) sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 49,084 shares — an estimated $5.51M sold.

Capital Fund Management (CFM) first reported a position in ALXN in Q2 2013 and held it in 10 quarters. The position peaked at $58.2M in Q2 2017. 707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

Capital Fund Management (CFM) reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Capital Fund Management (CFM) sold 49,084 Alexion Pharmaceuticals shares in Q3 2020, an estimated $5.51M.
Capital Fund Management (CFM) first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Capital Fund Management (CFM)'s Alexion Pharmaceuticals position peaked at $58.2M in Q2 2017.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2020, filed 13 Nov 2020.